Metformin eliminates lymphedema in mice by alleviating inflammation and fibrosis: implications for human therapy.

ABSTRACT:

Background

Secondary lymphedema is a chronic, disabling disease impacting over 50% of patients with cancer and lacking effective pharmacological treatment even for early- to mid-disease stages. Metformin reportedly exerts anti-inflammatory and anti-fibrotic effects and is safe, with minimal side effects; We investigated the role of metformin in lymphedema mouse models and examined underlying molecular mechanisms.

Methods

Male C57BL/6 mice (6-8-week-old; n=15/group) received metformin (300 mg/kg/day) by gavage on day 3 after lymphedema surgery; saline and sham groups were administered the same volume of saline. Hindlimb circumference and tail volume were monitored every two days. On day 28, samples were collected for histological assessment, western blotting, and reverse tran

SUBMITTER: Wei M 

PROVIDER: S-EPMC11584190 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature